TiGenix : completes EUR 12 million capital increase with strategic investor Grifols
(Thomson Reuters ONE) -
November 22, 2013
TiGenix completes EUR 12 million capital increase with strategic investor
Grifols
Leuven, Belgium - November 22, 2013, 12.15 p.m. - TiGenix NV (Euronext Brussels:
TIG) announced today the successful completion of the EUR 12 million capital
increaseannounced on November 20, 2013. In total, 34.188.034 new ordinary shares
were issued to Gri-Cel S.A., a fully-owned subsidiary of global healthcare
company Grifols S.A. TiGenix will prepare and, after approval by the FSMA,
publish a prospectus regarding the admittance of the new shares to trading on
NYSE Euronext Brussels, which is expected to take place in the following weeks.
The total number of outstanding ordinary shares in TiGenix NV as of November
22, 2013 amounts to 160,476,620.
"This is a very important milestone for the company. We are delighted to have
attracted Grifols as a long-term strategic investor and potential partner," said
Eduardo Bravo, CEO of TiGenix. "The funds allow us to continue to fully focus on
the completion of the Phase III trial with our lead product Cx601, and to
strengthen our commercial operations and the further roll-out of ChondroCelect.
Having such a reference shareholder increases our financial stability and
strengthens our position for future partnering negotiations with third parties."
"The investment in TiGenix clearly demonstrates Grifols' commitment to enter the
field of advanced therapies and personalized medicine, as well as its dedication
to innovative therapeutic approaches. I believe there is no better way to do so
than by investing in one of the global leaders in the field of mesenchymal stem
cell therapy," said Dirk Büscher, CEO of Gri-Cel. "For Grifols this is a
strategic investment with a long-term perspective, combined with the strong
belief in the technologies that have been and are being developed by TiGenix.
There is also the hope for additional future fruitful collaborations with
TiGenix taking advantage of the magnitude of Grifols' pipeline and products."
For more information
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company
with a marketed product for cartilage repair, ChondroCelect®, and a strong
pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.
About Grifols
Grifols is a global healthcare company with a 70-year legacy of improving
people's health and well being through the development of life-saving plasma
medicines, hospital pharmacy products and diagnostic technology for clinical
use.
As a leading producer of plasma medicines, Grifols has a presence in more than
100 countries and is the world leader in plasma collection, with 150 plasma
donation centers across the U.S. Grifols is committed to increasing patient
access to its life-saving plasma medicines through significant manufacturing
expansions and the development of new therapeutic applications of plasma
proteins. The company is headquartered in Barcelona, Spain and employs more than
11,000 people worldwide.
In 2012, Grifols' sales exceeded ?2,620 billion. The company's class A shares
are listed on the Spanish Stock Exchange, where they are part of the Ibex-35
(MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information
visit www.grifols.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1745162]
Unternehmensinformation / Kurzprofil:
Datum: 22.11.2013 - 12:15 Uhr
Sprache: Deutsch
News-ID 319557
Anzahl Zeichen: 7041
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 115 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : completes EUR 12 million capital increase with strategic investor Grifols"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
